A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Roche dumps another partnered asset.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
